Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-H6


Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
B7H6&CD3 BsAb - 01 PCC Solid Tumor Colorectal cancer,Lung cancer

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

 B7-H6 SPR

Biotinylated Human B7-H6, His,Avitag (Cat. No. B76-H82E5) immobilized on SA Chip can bind Human NKp30, His Tag (Cat. No. NC3-H5228) with an affinity constant of 0.213 μM as determined in a SPR assay (Biacore T200) (Routinely tested).


Immobilized Human NKp30, Fc Tag (Cat. No. NC3-H5259) at 5 μg/mL (100 μL/well) can bind Cynomolgus B7-H6 Protein, His Tag (Cat. No. B76-C52Ha) with a linear range of 0.625-5 μg/mL (QC tested).

Synonym Name

B7-H6,NCR3LG1,B7 Homolog 6


The B7 family of genes is essential in the regulation of the adaptive immune system. one of which is the recently discovered B7H6. Humans and rats have a single B7H6 gene; however, many B7H6 genes were detected in a single large cluster in the Xenopus genome. Chimeric antigen receptor (CAR) T-cell therapies have demonstrated durable and potentially curative therapeutic efficacy against B-cell leukemia in clinical trials. In this study, B7H6, a ligand for the NK cell activating receptor NKp30, was targeted to create a CAR that targets multiple tumor types. B7H6 is expressed on various primary human tumors, including leukemia, lymphoma and gastrointestinal stromal tumors, but it is not constitutively expressed on normal tissues.

Clinical and Translational Updates

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message